Abstract
The possible cardiovascular pharmacodynamic interactions at rest and during exercise of combining oral flosequinan (100 mg) with xamoterol (200 mg) was investigated in a four-way randomised double-blind placebo-controlled crossover trial in eight healthy male volunteers.
Xamoterol was better tolerated than flosequinan. The most common adverse events were mild to moderate headache and facial flushing. One volunteer developed headache and vomiting following flosequinan treatment and was replaced. Compared to placebo, at supine rest, flosequinan significantly increased heart rate (HR) by 5 beats·minv1, but had no effect on cardiac output (CO), stroke volume (SV) and mean blood pressure (MBP). Xamoterol significantly increased CO by 1.5 l·min-1, HR (5 beats·min-1) and MBP (6 mmHg) but not SV. The combined treatment (flosequinan + xamoterol) significantly increased CO (1.71·min-1) and HR (10 beats·min-1), but had no effect on SV and MBP. During exercise, flosequinan had no significant effect on any variable compared to placebo. Both xamoterol and combined treatment reduced the increase in CO (-4.61·min-1 after xamoterol and -3.41·min-1 after combined treatment vs. 0.1 l·min-1 after placebo), but had no effect on other variables.
The effect of the combined treatment on each haemodynamic variable were no more than the anticipated additive effects of the two drugs. Thus, no cardiovascular pharmacodynamic interaction was found between flosequinan and xamoterol in healthy volunteers.
Similar content being viewed by others
References
Cowley AJ, Wynne RD, Hampton JR (1984) The effects of BTS 49 465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers. J Hyperten 2 [Suppl 3]: 547–549
Lang D, Lewis MJ (1992) The effects of flosequinan on endothelin-1-induced changes in inositol 1,4,5-trisphosphate levels and protein kinase C activity in rat aorta. Eur J Pharmacol 226: 259–264
Wynne RD, Crampton EL, Hind ID (1985) The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers. Eur J Clin Pharmacol 28: 659–664
Cowley AJ, Wynne RD, Hampton JR (1987) Flosequinan as a third agent for the treatment of hypertension: a placebo controlled, double-blind study. Eur J Clin Pharmacol 33: 203–204
Snow HM (1989) The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart. Br J Clin Pharmacol 28 [Suppl]: 3S-13S
Fitzgerald DE (1989) Effect of xamoterol on peripheral blood vessels in healthy subjects. Br J Clin Pharmacol 28 [Suppl]: 70S-72S
Virk SJS, Davies MK (1989) Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure. Br J Clin Pharmacol 28 [Suppl]; 15S-22S
Nuttall A, Snow HM (1982) The cardiovascular effects of ICI 118587: a β1-adrenoceptor partial agonist. Br J Pharmacol 77: 381–388
Barnett DB (1993) Flosequinan. Lancet 341: 733–736
Ng HWK, Walley T, Tsao Y, Breckenridge AM (1991) Comparison and reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers. Br J Clin Pharmacol 32: 275–282
Cowley AJ, Wynne RD, Stainer K, Fullwood L, Rowley JM, Hampton JR (1988) Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. Br Med J 297: 169–173
Kessler PD, Packer M (1987) Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am Heart J 113: 137–143
Sramek BB (1989) Hemodynamic and pump-performance monitoring by electrical bioimpedance. Probl Resp Care 2: 274–290
Duranteau J, Pussard E, Edouard A, Samii K, Berdeaux A, Giudicelli JF (1992) Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers. Br J Clin Pharmacol 34: 207–214
Thomas SHL, Cooper RC, Ekwuru M, Fletcher S, Gilbody J, Husseyin TS, Ishaque M, Jagathesen R, Reddy G, Smith SE (1992) Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography. Eur J Clin Pharmacolol 42: 47–53
Armitage P, Berry G (1991) Comparison of several groups. In: Statistical methods in medical research. Blackwell, Oxford, pp 186–213
Haas GJ, Binkley PF, Carpenter JA, Leier CV (1989) Central and regional hemodynamic effects of flosequinan for congestive heart failure. Am J Cardiol 63: 1354–1359
Anonymous (1993) Flosequinan withdrawn. Lancet 342: 235
Hashimoto T, Shina A, Toyo-oka T, Hosada S, Kondo K (1986) The cardiovascular effects of xamoterol, a β1-adrenoceptor partial agonist, in healthy volunteers at rest. Br J Clin Pharmacol 21: 259–265
Marlow HF, Wardleworth AG, Booth LM (1982) The haemodynamic effects of oral doses of ICI 118,587, a β-adrenoceptor partial agonist, in healthy volunteers (abstract). Br J Clin Pharmacol 13: 269P-270P
Tangø M, Carlsen JE, Trap-Jensen J (1985) Immediate central and regional haemodynamic effects of a new beta1-adrenergic stimulating drug, Xamoterol (Corwin) in healthy volunteers. Eur J Clin Pharmacol 29: 155–158
Sato H, Inoue M, Matsuyama T, Ozaki H, Shimazu T, Takeda H, Ishida Y, Kamada T (1987) Hemodynamic effects of the β1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation 75: 213–220
Xamoterol In Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336: 1–6
Editorial (1990) New evidence on xamoterol. Lancet 336: 24
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ng, H.W.K., Walley, T.J., Tsao, Y. et al. Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. Eur J Clin Pharmacol 46, 361–365 (1994). https://doi.org/10.1007/BF00194406
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00194406